Gianluca Rotino Net Worth

Mr. Gianluca Rotino biography

Gianluca Rotino is the Chief Strategy & Innovation Officer and Director at Kiromic BioPharma.

What is the salary of Mr Rotino?

As the Chief Strategy & Innovation Officer and Director of Kiromic BioPharma, the total compensation of Mr Rotino at Kiromic BioPharma is 4,814,700$. There are no executives at Kiromic BioPharma getting paid more.

How old is Mr Rotino?

Mr Rotino is 49, he's been the Chief Strategy & Innovation Officer and Director of Kiromic BioPharma since . There are 5 older and 1 younger executives at Kiromic BioPharma. The oldest executive at Kiromic BioPharma, Inc. is Dr. David M. Spencer, 59, who is the Chief Scientific Officer.

What's Mr Rotino's mailing address?

Gianluca's mailing address filed with the SEC is C/O KIROMIC BIOPHARMA INC., 7707 FANNIN, SUITE 140, HOUSTON, TX, 77054.

Insiders trading at Kiromic BioPharma

Over the last 4 years, insiders at Kiromic BioPharma have traded over 0$ worth of Kiromic BioPharma stock and bought 29,599 units worth 105,539$ . The most active insiders traders include Jerry A. Schneider、Scott Dahlbeck、Pietro Bersani. On average, Kiromic BioPharma executives and independent directors trade stock every 99 days with the average trade being worth of 7,923$. The most recent stock trade was executed by Pietro Bersani on 23 August 2024, trading 3,488 units of KRBP stock currently worth 7,395$.

What does Kiromic BioPharma do?

Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell to target solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; and ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1. It has license agreements with CGA 369 Intellectual Holdings, Inc. and Longwood University, as well as a research and development collaboration agreement with Molipharma, S.R.L. The company also has strategic alliance agreement with Leon Office (H.K.) Ltd. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.

Kiromic BioPharma executives and stock owners

Kiromic BioPharma executives and other stock owners filed with the SEC include:

• Gianluca Rotino,
  Chief Strategy & Innovation Officer and Director
• Dr. Maurizio Chiriva Internati Ph.D.,
  Founder, Chairman, CEO & Pres
• Pietro Bersani CPA, J.D.,
  CEO & Director
• Dr. Leonardo Mirandola Ph.D.,
  Chief Scientific Officer
• Dr. Michael Ryan Ph.D.,
  Chief Bioinformatics Research Computing Officer
• Dr. Scott Dahlbeck Pharm.D., M.D., PharmD,
  Chief Medical Officer
• Dr. David M. Spencer,
  Chief Scientific Officer
• Daniel Clark,
  Chief Financial Officer
• Shannon Ralston,
  10% owner
• Michael Catlin,
  Director
• Pamela Misajon,
  Director
• Karen Reeves,
  Director
• Americo Cicchetti,
  Director
• Francis X Tirelli,
  Director
• Michael Nagel,
  Director
• Jerry A. Schneider,
  Director
• Pietro Bersani,
  Chief Executive Officer
• Scott Dahlbeck,
  Chief of Staff
• Tony Tontat,
  CFO & COO
• Ignacio Nunez,
  CHIEF OPERAT. AND MANUF. OFFI.
• Gianluca Rotino,
  CHIEF STRAT & INNOV OFFICER
• Michael Charles Ryan,
  See Remarks
• Internati Maurizio Chiriva,
  CHIEF EXECUTIVE OFFICER
• Daniel Grant Clark,
  Chief Financial Officer
• Brian Hungerford,
  Chief Financial Officer